BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19406725)

  • 1. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
    Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
    Dimopoulos MA; Delforge M; Hájek R; Kropff M; Petrucci MT; Lewis P; Nixon A; Zhang J; Mei J; Palumbo A
    Haematologica; 2013 May; 98(5):784-8. PubMed ID: 23242595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
    Delforge M; Minuk L; Eisenmann JC; Arnulf B; Canepa L; Fragasso A; Leyvraz S; Langer C; Ezaydi Y; Vogl DT; Giraldo-Castellano P; Yoon SS; Zarnitsky C; Escoffre-Barbe M; Lemieux B; Song K; Bahlis NJ; Guo S; Monzini MS; Ervin-Haynes A; Houck V; Facon T
    Haematologica; 2015 Jun; 100(6):826-33. PubMed ID: 25769541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.
    Cho YK; Irby DJ; Li J; Sborov DW; Mould DR; Badawi M; Dauki A; Lamprecht M; Rosko AE; Fernandez S; Hade EM; Hofmeister CC; Poi M; Phelps MA
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):748-758. PubMed ID: 30343510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors.
    Topf V; Kheifetz Y; Daum S; Ballhausen A; Schwarzer A; Trung KV; Stocker G; Aigner A; Lordick F; Scholz M; Knödler M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):6989-6998. PubMed ID: 36854800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
    Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
    Rajkumar SV; Jacobus S; Callander NS; Fonseca R; Vesole DH; Williams ME; Abonour R; Siegel DS; Katz M; Greipp PR;
    Lancet Oncol; 2010 Jan; 11(1):29-37. PubMed ID: 19853510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
    Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
    Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
    Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; López de la Guía A; López J; Bengoechea E; Pérez M; Polo M; Palomera L; de Arriba F; González Y; Hernández JM; Granell M; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Lahuerta JJ; Bladé J; San-Miguel JF
    Blood; 2012 Sep; 120(13):2581-8. PubMed ID: 22889759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
    Jakubowiak AJ; Dytfeld D; Griffith KA; Lebovic D; Vesole DH; Jagannath S; Al-Zoubi A; Anderson T; Nordgren B; Detweiler-Short K; Stockerl-Goldstein K; Ahmed A; Jobkar T; Durecki DE; McDonnell K; Mietzel M; Couriel D; Kaminski M; Vij R
    Blood; 2012 Aug; 120(9):1801-9. PubMed ID: 22665938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
    Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
    Kumar S; Flinn I; Richardson PG; Hari P; Callander N; Noga SJ; Stewart AK; Turturro F; Rifkin R; Wolf J; Estevam J; Mulligan G; Shi H; Webb IJ; Rajkumar SV
    Blood; 2012 May; 119(19):4375-82. PubMed ID: 22422823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.